Skip to content

Main Navigation

Vor Bio
  • News & Media
  • Publications
  • Join Us
  • Contact
  • Blog
  • Search
  • About Us
    • Overview
    • Vision, Mission, and Values
    • Our People
    • Leadership
    • Board of Directors
    • Scientific & Clinical Advisors
    • Founding Story
  • Approach
    • Overview
    • The Opportunity
    • The Concept
    • The Science
    • Programs
    • Manufacturing
    • Partnerships
  • Platform & Pipeline
    • Overview
    • Our Platform
    • Our Pipeline
  • Patients & Caregivers
    • Overview
    • Our Investigational Treatment Approach
    • Clinical Trials
    • The Patient/Donor Journey
    • Patient Advocacy
  • Medical Professionals
    • Overview
    • Our Investigational Program
    • Clinical Trials
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Contact IR
    • Email Alerts

Archives: Publications

ISMB – 2022 – Poster Presentation 859

TransACT enhances detection and characterization of translocation events from high-throughput sequencing data at base-pair resolution for gene editing products […]

Read More… from ISMB – 2022 – Poster Presentation 859

EHA – 2022 – Poster Presentation 1429

Multiplex Deletion of Myeloid Antigens CD33 and CLL-1 by CRISPR/Cas9 in Human Hematopoietic Stem Cells Highlights the Potential of Next-Generation Transplantation for AML Treatment […]

Read More… from EHA – 2022 – Poster Presentation 1429

ASGCT – 2022 – Poster Presentation Tu-117

A Novel Scalable Electroporation Platform for the Manufacturing of Gene Modified Hematopoietic Stem and Progenitor Cell Therapies […]

Read More… from ASGCT – 2022 – Poster Presentation Tu-117

ISGCT – 2022 – Poster Presentation 933

Novel Automated, Functionally Closed System for Rapid Immunomagnetic Negative Selection of T Cells […]

Read More… from ISGCT – 2022 – Poster Presentation 933

Keystone Symposia – 2022 – Poster Presentation 3002

Multiplex Editing of Hematopoietic Stem and Progenitor Cells (HSPCs) with CRISPR Cas Nucleases Achieves High On Target Editing with Undetectable Translocations […]

Read More… from Keystone Symposia – 2022 – Poster Presentation 3002

Keystone Symposia – 2022 – Poster Presentation 3001

Multiplex Base Editing in Human Hematopoietic Stem and Progenitor Cells (HSPCs) Enables Efficient Removal of Multiple Surface Antigens in Acute Myeloid Leukemia (AML) Immunotherapy […]

Read More… from Keystone Symposia – 2022 – Poster Presentation 3001

ASH Annual Meeting 2021 – Poster Presentation 1716

G-CSF/Plerixafor Dual-Mobilized Donor Derived CD33CAR T-Cells as Potent and Effective AML Therapy in Pre-Clinical Models […]

Read More… from ASH Annual Meeting 2021 – Poster Presentation 1716

ASH Annual Meeting 2021 – Poster Presentation 2939

Multiplex Engineering of Human CD34+ HSPCs Enables Dual Gene Knockout While Maintaining High Engraftment Potential and Safety […]

Read More… from ASH Annual Meeting 2021 – Poster Presentation 2939

ASH Annual Meeting 2021 – Poster Presentation 3818

Knock Out of CD123 or CLL-1 by CRISPR-Cas9 Editing From Human Hematopoietic Stem Cell Transplantations Provide New Possibilities for Increasing Therapeutic Index and Safety for AML Treatment […]

Read More… from ASH Annual Meeting 2021 – Poster Presentation 3818

Posts navigation

  • 1
  • 2
  • »

Share This Post

Recent Posts

  • The Online Reflection of Vor Bio August 2, 2022
Logo Vor Biopharma White

Follow us on social media:

Twitter LinkedIn
  • About Us
    • Vision, Mission, and Values
    • Our People
    • Leadership
    • Board of Directors
    • Scientific & Clinical Advisors
    • Founding Story
  • Approach
    • The Opportunity
    • The Concept
    • The Science
    • Programs
    • Manufacturing
    • Partnerships
  • Platform & Pipeline
    • Our Platform
    • Our Pipeline
  • Patients & Caregivers
    • Our Investigational Treatment Approach
    • Clinical Trials
    • The Patient/Donor Journey
    • Patient Advocacy
  • Medical Professionals
    • Our Investigational Program
    • Clinical Trials
  • Investors
    • News Releases
    • Events & Presentations
    • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Contact IR
    • Email Alerts
  • News & Media
  • Publications
  • Join Us
  • Blog

© 2022 Vor Biopharma

  • Privacy Policy
  • Terms of Use
Recruiting Guidelines

All employment opportunities at Vor Biopharma are managed by our in-house Human Resources Department. Therefore, agency staff and independent recruiters must contact the Human Resources Department directly in order to present candidates or inquire about openings. Please do not contact other Vor Bipharma employees. Your ability to comply with this request will significantly impact any decision we may make about doing business with you.

Please understand that we do not accept unsolicited resumes from any source other than from the candidates themselves. Any agency or independent recruiter must have a signed copy of our agency agreement before presenting candidates. Submission of unsolicited resumes without our signed agreement will not create any implied obligation on our part.

If you wish to be considered for the presentation of candidates, please contact us through careers@vorbio.com. Attach your contact information, your area of specialty, and any marketing information you wish to provide. Someone from the Human Resources Department will contact you directly if there is a business need for your services.